Pro­teosta­sis shares shat­tered as weak triplet da­ta in­spires a scorch­ing back­lash

You al­most have to pity Pro­teosta­sis $PTI to­day. The mi­cro-cap biotech sal­lied out in­to the stock mar­ket ear­ly in the day try­ing to float some mediocre ef­fi­ca­cy re­sults for their triple for cys­tic fi­bro­sis and got gunned down on every side. 

Al­ready quick to en­tice skep­ti­cism af­ter ear­li­er shots on goal aroused a short at­tack from Ker­ris­dale Cap­i­tal, some promi­nent an­a­lysts made short work of Pro­teosta­sis’ num­bers this morn­ing. Its share price is down 65% to an all-time low and the mar­ket cap has shriv­eled to a pal­try $76 mil­lion — less than cur­rent as­sets on hand.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER